T0	Participants 151 247	320 multiple myeloma (MM) patients entering the German Myeloma Treatment Group (GMTG) trial MM01
T1	Participants 959 1061	poor prognosis patients (50% TRS: 16 months) characterised by pretreatment platelets of < or = 150,000
T2	Participants 1116 1150	Patients lacking both risk factors